Rein Therapeutics Inc.
RNTX | NASDAQ
$0.79
-$0.01 (-1.25%)
At close: Sep 21, 2026, 4:00 PM ET
$0.80
+$0.01 (+1.27%)
Pre-market:
Sep 22, 2026, 4:06 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -1K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -21.93M | -65.11M | -16.28K | -27.65K | -26.61K | -20.5K |
Interest Income | n/a | 400K | 600 | n/a | n/a | n/a |
Pretax Income | -50.58M | -64.31M | -15.73K | -27.33K | -26.16K | -21.16K |
Net Income | -49.87M | -62.88M | -15.73K | -27.33K | -26.16K | -21.16K |
Selling & General & Admin | 10.9M | 13.86M | 11.36K | 9.68K | 9.6K | 9.33K |
Research & Development | 11.03M | 14.25M | 3.99K | 17.97K | 17.01K | 11.17K |
Other Expenses | -1K | 37M | 928 | n/a | n/a | n/a |
Operating Expenses | 21.93M | 65.11M | 16.28K | 27.65K | 26.61K | 20.5K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 21.93M | 65.11M | 16.28K | 27.65K | 26.61K | 20.5K |
Income Tax Expense | -712K | -1.54M | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 25.44M | 17.94M | 4.6M | 4.54M | 4.44M | 17.43M |
Shares Outstanding (Diluted) | 25.44M | 17.94M | 4.6M | 4.54M | 4.44M | 17.43M |
EPS (Basic) | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | 0 |
EPS (Diluted) | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | 0 |
EBITDA | -50.58M | -28.05M | -15.23K | -27.16K | -26.04K | -20.33K |
EBIT | -50.58M | -28.11M | -15.35K | -27.33K | -26.16K | -20.5K |
Depreciation & Amortization | 1K | 63K | 119 | 169 | 121 | 163 |
Add to Watchlist
Select watchlists to add or remove RNTX